Feature | Stents | July 31, 2015

Trio of Drug-Eluting Stents Driving European Interventional Cardiology Market

Abbott Laboratories, Boston Scientific and Medtronic offsetting 10 percent overall decline in 2014

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

July 31, 2015 — According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents accounted for a significant portion of the European markets for interventional cardiology devices in 2014. The advent of drug-eluting stents has driven the interventional cardiology market beyond expectations, as these devices have managed to increase the size of the market by virtue of their relatively high average selling price (ASP). New developments in drug-eluting stents such as biodegradable materials are expected to keep the market competitive despite safety concerns regarding late stent thrombosis.

In 2014, the European markets for interventional cardiology were valued at nearly EUR 1.3 billion, a nearly 10 percent decrease from the previous year. The total European market for interventional cardiology devices is projected to decline as a result of continued decrease in average selling prices due to:

The competitive tender systems being adopted across Europe;
Low procedure numbers; and
A decrease in devices used per procedure due to improvements in medical devices and cardiologist best practices.

 

"Unit sales growth is expected to be driven by a new generation of drug-eluting stents, which are expected to alleviate physician concerns over thrombosis issues, as well as decreased ASPs which may trigger physicians to stent more," explained Kamran Zamanian, Ph.D., CEO of iData.

The negative growth experienced throughout many countries over 2011 and 2012 was due primarily to turbulent macroeconomic conditions throughout the European region. The United Kingdom showed the largest decline due to the entrance of substantially lower priced products being brought into the country from Germany. Benelux and Spain are also expected to see large market declines due to prevalent price erosion and the lackluster unit sales growth in their respective markets. Spending cuts throughout many countries and uncertainty regarding default were major contributors to the stifling of growth of many markets. Austria is expected to be the only country to experience growth due to its premium pricing system modeled after the Swiss market and its proximity to the leading German market.

Abbott Laboratories has been the leading competitor in the drug-eluting stent (DES) market with more than 30 percent market share. Their actual selling price for DES has been quite low due to competition with Boston Scientific. Other competitors include Medtronic, Biotronik, B. Braun, Biosensors International, Cornova and Disa Vascular, among others.

For more information: www.idataresearch.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init